In vivo thermoluminescence dosimetry dose verification of transperineal 192Ir high-dose-rate brachytherapy using CT-based planning for the treatment of prostate cancer

Anagnostopoulos, Georgios C.; Baltas, Dimos; Geretschlaeger, Andreas; Martin, Thomas J.; Papagiannis, Panagiotis; Tselis, Nikolaos; Zamboglou, N.

doi:10.1016/s0360-3016(03)00762-4

Cited by 49 publications

(34 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these results, we used the same approach of generating a single treatment plan after implantation for the following four fractions of HDR brachytherapy. In our series, we performed CT-based 3-D postplanning directly after implantation [1,14,37]. The isodose distribution was evaluated in all CT slices within and surrounding the prostate and within normal tissues (Figure 4).…”

Section: Discussionmentioning

confidence: 99%

3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…TLDs have given good results for HDR prostate brachytherapy IVD [8][9][10] but do not allow a real time measurement approach. Haughey et al [11] used a metal-oxide semiconductor field effect transistor (MOSFET) linear array inside the rectum during HDR prostate brachytherapy but concluded that the approach was not suitable due to the difficulties of quantifying uncertainties in MOSFET response.…”

Section: Introductionmentioning

confidence: 99%

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Mason¹,

Mamo²,

Al-Qaisieh³

et al. 2016

Radiotherapy and Oncology

View full text Add to dashboard Cite

Material and methods IVD was performed for 40 treatments planned using intra-operative trans-rectal ultrasound (TRUS) with a MOSFET inserted into an additional needle. Post-treatment TRUS images were acquired for 20 patients to assess needle movement. Monte Carlo simulations of treatment plans were performed for 10 patients to assess impact of heterogeneities.Per-needle and total plan uncertainties were estimated and retrospectively applied to the measured data as error detection thresholds. ResultsThe mean measured dose was -6.4% compared to prediction (range +5.1% to -15.2%). Needle movement and heterogeneities accounted for -1.8% and -1.6% of this difference respectively (mean values for the patients analysed). Total plan uncertainty (k=2) ranged from 11% to 17% and per needle uncertainty (k=2) ranged from 18% to 110% (mean 31%). One out of 40 plans and 5% of needles were outside k=2 error detection threshold. Conclusions

show abstract

“…The lowest energy included in these studies is 1.17 MeV ( 60 Co) and a backscatter dose enhancement range of a few millimetres was obtained. Since the average energy of the encapsulated 192 Ir is around 360 keV (Ash et al 2002) with a primary emission spectrum that extends to approximately 612 keV (Rivard et al 2010) and an additional component of secondary scattered photons which accumulate in the low-energy peak around 60 keV (Anagnostopoulos et al 2003), the range of backscatter electrons is expected to be very short.…”

Section: Discussionmentioning

confidence: 99%

Radiation dose enhancement at tissue-tungsten interfaces in HDR brachytherapy

et al. 2014

View full text Add to dashboard Cite

HDR BrachyView is a novel in-body dosimetric imaging system for real-time monitoring and verification of the source position in high dose rate (HDR) prostate brachytherapy treatment. It is based on a high-resolution pixelated detector array with a semi-cylindrical multi-pinhole tungsten collimator and is designed to fit inside a compact rectal probe, and is able to resolve the 3D position of the source with a maximum error of 1.5 mm. This paper presents an evaluation of the additional dose that will be delivered to the patient as a result of backscatter radiation from the collimator. Monte Carlo simulations of planar and cylindrical collimators embedded in a tissue-equivalent phantom were performed using Geant4, with an 192 Ir source placed at two different sourcecollimator distances. The planar configuration was replicated experimentally to validate the simulations, with a MOSkin dosimetry probe used to measure dose at three distances from the collimator. For the cylindrical collimator simulation, backscatter dose enhancement was calculated as a function of axial and azimuthal displacement, and dose distribution maps were generated at three distances from the collimator surface. Although significant backscatter dose enhancement was observed for both geometries immediately adjacent to the collimator, simulations and experiments indicate that backscatter dose is negligible at distances beyond 1 mm from the collimator. Since HDR BrachyView is enclosed within a 1 mm thick tissue-equivalent plastic shell, all Institute of Physics and Engineering in Medicine

show abstract

In vivo thermoluminescence dosimetry dose verification of transperineal 192Ir high-dose-rate brachytherapy using CT-based planning for the treatment of prostate cancer

Cited by 49 publications

References 33 publications

3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer

3-D Conformal HDR Brachytherapy as Monotherapy for Localized Prostate Cancer

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Radiation dose enhancement at tissue-tungsten interfaces in HDR brachytherapy

Contact Info

Product

Resources

About